Orlando, FL Clinical Trials Report — May 2026

For Orlando residents interested in contributing to medical research, May 2026 brings both urgent opportunities and significant new avenues for participation. Across Orlando, a total of 693 clinical trials are currently recruiting across 354 research facilities, offering diverse ways to engage with medical advancements.

A total of 52 clinical trials in Orlando are scheduled to conclude within the next 90 days, making prompt action essential for interested individuals. This urgency is particularly relevant for healthy volunteers, as 12 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions, including liver and kidney issues, and different types of cancer, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Hepatic impairment (3 trials)
• Breast cancer (3 trials)
• Renal impairment (3 trials)
• Colorectal cancer (2 trials)
• Irritable bowel syndrome with constipation (IBS-C) (2 trials)
• Advanced breast cancer (2 trials)
• Attention-deficit/hyperactivity disorder (1 trial)
• Apraxia, oral (1 trial)
• Advanced NSCLC (1 trial)

Additionally, 2 trials specifically seeking healthy volunteers are also nearing their enrollment deadlines, providing a time-sensitive opportunity for those without specific conditions to participate.

New Research Opportunities Emerge in Orlando

This month, Orlando saw the opening of 9 new clinical trials, maintaining the pace of new research opportunities compared to the 9 trials that launched in April 2026. This brings fresh avenues for participation across a range of health challenges.

New trials this month are exploring a variety of conditions, with obesity being the most frequent. Other conditions include amyloid, cognitive dysfunction, dementia, heart failure, lewy body disease, lipoprotein (a), lupus nephritis, major depressive disorder, and multiple sclerosis. Drug trials account for the largest share of new studies, with 7 new drug trials, alongside 2 "other" types of studies, 1 biological, and 1 procedure trial.

Notable New Trials from Major Sponsors

May brings several high-profile new trials to Orlando, including significant Phase 2 and Phase 3 studies from major sponsors like Novo Nordisk A/S and Eli Lilly and Company. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches.

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• Eli Lilly and Company is sponsoring NCT07602582, a Phase 3 study titled "A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT)." This study, involving 550 participants, aims to determine if participants who previously took donanemab receive clinical benefit from annual doses, with each participant's involvement lasting up to 2.5 years.
• Another significant study from Eli Lilly and Company is NCT07589608, a Phase 2 trial titled "A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight." This study, aiming for 400 participants, will examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in individuals with obesity or overweight without type 2 diabetes.
• Eli Lilly and Company is also behind NCT07589595, a Phase 2 study titled "A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)." This trial, involving 350 participants, seeks to evaluate whether treatment with donanemab slows the progression of cognitive and functional decline.
• Definium Therapeutics US, Inc. is sponsoring NCT07592689, a Phase 3 trial titled "A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)." This double-blind, placebo-controlled study, with an open-label extension, will evaluate DT120 compared to placebo in major depressive disorder, involving 165 participants.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are opportunities to contribute to research. Of the 9 new trials launched this month, 1 is actively seeking healthy volunteers. Across Orlando, a total of 70 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Orlando's Leading Research Facilities

Orlando is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• AdventHealth Orlando (59 trials)
• Arnold Palmer Hospital for Children (39 trials)
• Nemours Children's Hospital (36 trials)
• Orlando Health (34 trials)
• Orlando Health Cancer Institute (33 trials)
• University of Central Florida (28 trials)
• Research Site (25 trials)
• AdventHealth (25 trials)
• Advent Health (17 trials)
• Orlando Clinical Research Center (15 trials)
• Florida Cancer Specialists (12 trials)
• Advent Health Orlando (11 trials)

These institutions offer a broad spectrum of research, from general medical studies at AdventHealth Orlando and Orlando Health, to specialized pediatric research at Arnold Palmer Hospital for Children and Nemours Children's Hospital, and oncology research at Orlando Health Cancer Institute and Florida Cancer Specialists.

Broadening Your Search: Nearby Options in Florida

While Orlando offers a robust array of clinical trial opportunities, individuals may also find options in nearby communities within Florida. Cities with active trials include Miami (23 trials), Jacksonville (12 trials), Tampa (9 trials), Winter Park (6 trials), Gainesville (6 trials), Maitland (5 trials), Miami Lakes (4 trials), and Coral Gables (4 trials). Exploring these nearby locations can expand the possibilities for participation.

Participation in clinical trials is open to a diverse range of individuals. Of the 9 new trials launched this month, all include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. No new trials are exclusively for children, females, or males this month. Industry sponsors, such as Eli Lilly and Company and Novo Nordisk A/S, are driving the majority of new research efforts, with 7 new industry-sponsored trials this month.

As we move further into spring, Orlando's growing research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.